Article

Early Cancer Diagnosis, Treatment Saves More Lives

The World Health Organization seeks to improve early cancer detection to increase survivors and cut treatment costs.

In an effort to improve cancer survival rates, the World Health Organization (WHO) launched a report with a goal to ensure health services place greater focus on early diagnosis and treatment, according to Reuters.

“Diagnosing cancer in late stages, and the inability to provide treatment, condemns many people to unnecessary suffering and early death,” Etienne Krug, WHO expert on cancer and chronic diseases, told Reuters.

Early diagnosis followed by prompt cancer treatment would help more individuals survive the disease, particularly in breast cancer, cervical cancer, and colorectal cancer, according to Krug.

Furthermore, early detection could significantly cut down on treatment costs, thereby reducing the financial impact of the disease.

“Not only is the cost of treatment much less in cancer’s early stages, but people can also continue to work and support their families if they can access effective treatment in time,” the WHO report stated.

Many poorer countries are faced with more significant challenges due to a lack of diagnostics services and treatments. The WHO urges these countries to prioritize basic, high-impact, and low-cost cancer diagnosis and treatment services.

Cancer accounts for an estimated 1 in 6 deaths worldwide, according to the WHO report. In 2010, the annual combined cost of health care and loss of productivity was approximately $1.16 trillion.

Each year, more than 14 million individuals develop cancer, killing 8.8 million people per year. According to the WHO, this number is projected to increase to more than 21 million by 2030.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards